Transparency Market Research, in its latest report, states that the global hypertrophic cardiomyopathy therapeutics market is anticipated to witness tepid growth over the next seven years. Thoroughly analyzing the performance of the market from 2015 to 2023, the report – titled “Hypertrophic Cardiomyopathy Therapeutics Market – (By Drug Class: Beta Adrenergic Blocking Agents, Calcium Channel Blocker, Antiarrhythmic Agents, and Anticoagulants) – Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 – 2023” – reveals that the global hypertrophic cardiomyopathy therapeutics market is forecast to rise from a value of US$1.2 bn in 2014 to US$1.4 bn in 2023, registering a 1.40% CAGR during that time.
Download exclusive Sample of this report:
The rising prevalence of chronic cardiovascular diseases, increased awareness about hypertrophic cardiomyopathy, and the growing demand for effective treatments options are the key factors fueling the hypertrophic cardiomyopathy therapeutics market. However, technological upgradation in devices such as pacemakers and defibrillators hampers the demand for hypertrophic cardiomyopathy drugs.
In order to provide readers with a clear understanding of the structure, scope, and dynamics of the hypertrophic cardiomyopathy therapeutics market, the report segments the overall market based on drug class and geography.
On the basis of drug class, the hypertrophic cardiomyopathy therapeutics market is categorized into calcium channel blockers, anticoagulants, beta adrenergic blocking agents, and antiarrhythmic agents. By revenue, calcium channel blockers held the largest share in 2014 and this trend is likely to continue through 2023 with the segment expanding at a 1.80% CAGR during that time. By demand, beta adrenergic blocking agents dominated the market given that they are the first choice for treatment of obstructive and non-obstructive hypertrophic cardiomyopathy.
View exclusive Global strategic Business report :
On the basis of geography, the global hypertrophic cardiomyopathy therapeutics market is segmented into North America, Europe, Asia Pacific, and Rest of the World. Accounting for over 30.0% of the overall market in 2014, the US emerged as the leading regional segment of the hypertrophic cardiomyopathy therapeutics market, with Europe following suit. Both these markets are fueled by the rising obese population, availability of modern healthcare infrastructure, high awareness about hypertrophic cardiomyopathy, and sedentary lifestyle among the youth. Asia Pacific is projected to be the fastest developing regional segment of the hypertrophic cardiomyopathy therapeutics market by 2023 owing to development of healthcare infrastructure, increased prevalence of the cardiac ailments and complications, and growing awareness.
An interesting feature of the report on the hypertrophic cardiomyopathy therapeutics market is its assessment of the vendor landscape. Major competitors are identified and examined in detail. Some of the key players competing in the global hypertrophic cardiomyopathy therapeutics market are Gilead Sciences, Inc., Astra Zeneca plc, Novartis AG, Mylan N.V., Concordia Healthcare Corp., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., and Merck & Co., Inc. These competitors are profiled in the report based on attributes such as company and financial overview, product portfolio, recent developments, and business strategies.
Global Hypertrophic Cardiomyopathy Therapeutics, by Drug Class
• Beta Adrenergic Blocking Agents
• Calcium Channel Blockers
• Antiarrhythmic Agents
Global Hypertrophic Cardiomyopathy Therapeutics, by Geography
• North America
o Rest of Europe
• Asia Pacific
o Rest of Asia Pacific
• Rest of the World
o Latin America
o Middle East